Cargando…

Pain in adult patients with Pompe disease

Detalles Bibliográficos
Autores principales:	Karabul, N., Kruijshaar, M.E., Schober, A., Güngör, D., Hanisch, F.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2014
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5121288/ https://www.ncbi.nlm.nih.gov/pubmed/27896083 http://dx.doi.org/10.1016/j.ymgmr.2014.02.007

Ejemplares similares

Enzyme replacement therapy and antibodies in late-onset Pompe disease
por: Schneider, I., et al.
Publicado: (2014)

Impact of enzyme replacement therapy on survival in adults with Pompe disease
por: Güngör, Deniz, et al.
Publicado: (2013)

A conceptual disease model for adult Pompe disease
por: Kanters, Tim A., et al.
Publicado: (2015)

Cytokines in treated and untreated Pompe patients
por: Karabul, N, et al.
Publicado: (2013)

Enzyme replacement therapy and fatigue in adults with Pompe disease
por: Güngör, Deniz, et al.
Publicado: (2013)

Walking delay as leading symptom in late-onset Pompe disease
por: Gökce, S, et al.
Publicado: (2013)

Association of Muscle Strength and Walking Performance in Adult Patients With Pompe Disease
por: Favejee, Marein M, et al.
Publicado: (2018)

Late-onset Pompe disease manifests in the brain
por: Finsterer, Josef
Publicado: (2019)

Anaesthetic management of caesarean section in a patient with Pompe disease
por: Puthenveettil, Nitu, et al.
Publicado: (2021)

Impact of enzyme replacement therapy on survival in adults with Pompe disease: results from a prospective international observational study
por: Güngör, Deniz, et al.
Publicado: (2013)

Response: Late-onset Pompe disease manifests in the brain
por: Schneider, Ilka, et al.
Publicado: (2019)

Adenotonsillectomy should be avoided whenever possible in infantile-onset Pompe disease
por: Jones, Harrison N., et al.
Publicado: (2020)

Cost-effectiveness of enzyme replacement therapy with alglucosidase alfa in adult patients with Pompe disease
por: Kanters, Tim A., et al.
Publicado: (2017)

Enzyme replacement therapy reduces the risk for wheelchair dependency in adult Pompe patients
por: van der Meijden, Jan C., et al.
Publicado: (2018)

Dilative arteriopathy in Pompe disease may not only affect the cerebral arteries
por: Finsterer, Josef
Publicado: (2018)

Infantile onset Pompe disease presenting with non-immune hydrops fetalis
por: Lee, Kristen, et al.
Publicado: (2019)

Quality of life and participation in daily life of adults with Pompe disease receiving enzyme replacement therapy: 10 years of international follow-up
por: Güngör, Deniz, et al.
Publicado: (2015)

Functional capacity in a late-onset Pompe disease patient: Effect of enzyme replacement therapy and exercise training
por: Krase, Argyro A., et al.
Publicado: (2016)

Glycogenosome accumulation in the arrector pili muscle in Pompe disease
por: Katona, Istvan, et al.
Publicado: (2014)

Mild disease course of SARS-CoV-2 infections and mild side effects of vaccination in Pompe disease: a cohort description
por: Ismailova, G., et al.
Publicado: (2022)

Large variation in effects during 10 years of enzyme therapy in adults with Pompe disease
por: Harlaar, Laurike, et al.
Publicado: (2019)

Phenotypical variation within 22 families with Pompe disease
por: Wens, Stephan C A, et al.
Publicado: (2013)

Effects of exercise training in 23 adults with Pompe disease receiving enzyme therapy
por: van den Berg, Linda, et al.
Publicado: (2013)

Hearing in adults with Pompe disease
por: van der Beek, Nadine A. M. E., et al.
Publicado: (2011)

Lung MRI and impairment of diaphragmatic function in Pompe disease
por: Wens, Stephan CA, et al.
Publicado: (2015)

Late‐onset Pompe disease with a novel mutation and a rare phenotype: A case report
por: Si, Xiaoli, et al.
Publicado: (2022)

Pompe disease: a short comment
por: Nigro, Giovanni
Publicado: (2013)

Long-term follow-up of 17 patients with childhood Pompe disease treated with enzyme replacement therapy
por: van der Meijden, Jan C., et al.
Publicado: (2018)

Is early detection of late-onset Pompe disease a pneumologist’s affair? A lesson from an Italian screening study
por: Confalonieri, Marco, et al.
Publicado: (2019)

Curative Treatment of POMP-Related Autoinflammation and Immune Dysregulation (PRAID) by Hematopoietic Stem Cell Transplantation
por: Meinhardt, Andrea, et al.
Publicado: (2021)

Increased aortic stiffness and blood pressure in non-classic Pompe disease
por: Wens, Stephan C. A., et al.
Publicado: (2014)

Risk factors for osteoporosis, falls and fractures in hereditary myopathies and sporadic inclusion body myositis — A cross sectional survey()
por: Danckworth, F., et al.
Publicado: (2014)

CRIM-negative infantile Pompe disease: Characterization of immune responses in patients treated with ERT monotherapy
por: Berrier, Kathryn L., et al.
Publicado: (2015)

Minutes of the European POmpe Consortium (EPOC) Meeting March 27 to 28, 2015, Munich, Germany
por: Schoser, Benedikt, et al.
Publicado: (2015)

Positive association between physical outcomes and patient-reported outcomes in late-onset Pompe disease: a cross sectional study
por: Yuan, Meng, et al.
Publicado: (2020)

Obstetric risk in patients with myopathy due to MATR3 mutations
por: Mueller, T., et al.
Publicado: (2014)

The Pompe Registry: tracking Pompe disease symptoms in a broad patient population
por: Byrne, B, et al.
Publicado: (2008)

Extent, impact, and predictors of diagnostic delay in Pompe disease: A combined survey approach to unveil the diagnostic odyssey
por: Lagler, Florian B., et al.
Publicado: (2019)

Survival and associated factors in 268 adults with Pompe disease prior to treatment with enzyme replacement therapy
por: Güngör, Deniz, et al.
Publicado: (2011)

Home-Based Infusion of Alglucosidase Alfa Can Safely be Implemented in Adults with Late-Onset Pompe Disease: Lessons Learned from 18,380 Infusions
por: Ditters, Imke A. M., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_76tk44p9sfhv1o0liuqd36iq0d